Hisse Senetlerindeki Sıralama
#35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Hisse Fiyatı
$0.82959892
Son senkronizasyon: 2023-05-23
B piyasa değeri ile IMV fiyatı
Piyasa Değeri IMV Inc.(IMV)
Piyasa Değeri: $4.16M
August 2026 itibarıyla IMV Inc. şirketinin piyasa değeri $4.16M. Bu, verilerimize göre IMV Inc. şirketini dünyanın en değerli 35289th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
IMV Inc. piyasa değeri geçmişi (2012 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında IMV
| IMV’in Fiyatı |
|
B Varlığı |
B’nin Piyasa Değeri |
Sonuçlar |
|
|
|
|
$5.452T
|
+131,076,102.29%
|
|
|
|
|
$4.490T
|
+107,950,940.04%
|
|
|
|
|
$4.162T
|
+100,074,320.56%
|
|
|
|
|
$3.676T
|
+88,388,142.13%
|
|
|
|
|
$2.833T
|
+68,113,157.05%
|
